Filing Details

Accession Number:
0001387131-21-005571
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-05-12 13:00:00
Reporting Period:
2021-05-10
Accepted Time:
2021-05-12 20:44:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
25743 Therapeuticsmd Inc. TXMD Pharmaceutical Preparations (2834) 870233535
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1627810 C Michael Donegan 951 Yamato Road, Suite 220
Boca Raton FL 33431
Cao And Vp Finance No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-05-10 19,000 $0.00 19,000 No 4 M Direct
Common Stock Disposition 2021-05-11 4,842 $1.04 14,158 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2021-05-10 19,000 $0.00 19,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
38,000 No 4 M Direct
Footnotes
  1. On May 10, 2021, the reporting person received 19,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021.
  2. The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
  3. The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $1.03 to $1.06 for an average weighted sale price of $1.04. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  4. Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.
  5. The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.